<?xml version="1.0" encoding="UTF-8"?>
<p id="p0020">Many drug discovery groups have applied the drug repurposing or repositioning to speed-up and bring out curative therapy (
 <xref rid="bib7" ref-type="bibr">7</xref>). The repurposed drugs remdesivir and favipiravir are currently approved by US-FDA for treatment of COVID-19 act by inhibiting the viral RNA-dependent RNA polymerase (RdRp). These drugs have limitation in terms of its cost-effectiveness and adverse drug reactions such as hyperuricaemia, teratogenicity and QT-prolongation (
 <xref rid="bib8" ref-type="bibr">8</xref>,
 <xref rid="bib9" ref-type="bibr">9</xref>). Similarly, the anti-inflammatory and immunosuppressant class of drugs corticosteroids, such as dexamethasone, is approved by US-FDA. The corticosteroids have limitations in terms of its dose-dependent toxicities and drug-disease interactions.
</p>
